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Abstract
Decreasing costs of genetic testing and advances in treatment for women with cancer with 
germline BRCA1/BRCA2 mutations have heralded more inclusive genetic testing programs. 
The Genetic Testing in Epithelial Ovarian Cancer (GTEOC) Study, investigates the 
feasibility and acceptability of offering genetic testing to all women recently diagnosed with 
epithelial ovarian cancer (universal genetic testing or UGT). Study participants and staff were
interviewed to: (i) assess the impact of UGT (ii) integrate patients’ and staff perspectives in 
the development of new UGT programs. Semi-structured interviews were conducted with 
twelve GTEOC Study participants and five members of staff involved in recruiting them. The
transcripts were transcribed verbatim and analyzed using Interpretative Phenomenological 
Analysis. There are two super-ordinate themes: motivations and influences around offers of 
genetic testing and impacts of genetic testing in ovarian cancer patients. A major finding is 
that genetic testing is contextualized within the broader experiences of the women; the impact
of UGT was minimized in comparison with the ovarian cancer diagnosis. Women who 
consent to UGT are motivated by altruism and by their relatives’ influence, whilst those who 
decline are often considered overwhelmed or fearful. Those without a genetic mutation are 
usually reassured by this result, whilst those with a genetic mutation must negotiate new 
uncertainties and responsibilities towards their families. Our findings suggest that UGT in 
this context is generally acceptable to women. However, the period shortly after diagnosis is 
a sensitive time and some women are emotionally overburdened. UGT is considered a 
‘family affair’ and staff must acknowledge this.
Keywords: UK; BRCA1; BRCA2; Genetic counseling; Interpretive phenomenological 
analysis (IPA); Ovarian cancer; Oncology
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Background
Approximately 1.5% of women in the UK are diagnosed with epithelial ovarian cancer 
(EOC), and the five-year prognosis remains poor. Up to 15.5% of these women have a 
germline mutation in their BRCA1/BRCA2 genes (Zhang et al. 2011). Estimates indicate that
limitations of established genetic testing pathways via Clinical Genetics Services mean that 
only 60% of those with a germline BRCA1/BRCA2 gene mutation are identified (Metcalfe et
al. 2009). There is evidence that BRCA1/BRCA2 mutation status provides predictive 
information regarding likelihood of response to treatment, specifically to poly (ADP-ribose) 
polymerase (PARP) inhibitors (Gelmon et al. 2011; Ledermann et al. 2012, 2014). Indeed, 
Olaparib (Lynparza) has recently been approved by the National Institute for Health and Care
Excellence for treating eligible patients with relapsed, platinum sensitive cancer with 
BRCA1/BRCA2 mutations (National Institute for Health and Care Excellence 2016). 
Identifying more mutation carriers will increase the number of families where cascade 
genetic testing can be offered, thus increasing identification of female relatives at high risk of
EOC and breast cancer. Undertaking bilateral salpingo-oophorectomy in these women 
reduces the risk of EOC by 80–96% (Domchek et al. 2010; Kauff et al. 2008; Rebbeck et al. 
2009); furthermore, risk-reducing bilateral mastectomies significantly reduces the risk of a 
first diagnosis of breast cancer (Domchek et al. 2010). Despite the benefits of 
BRCA1/BRCA2 testing, concerns have been raised about testing too soon after (breast 
cancer) diagnosis, arguing that it may overburden women already weighed down with their 
cancer diagnoses (Ardern-Jones et al. 2005). As genetic testing becomes increasingly 
integrated into mainstream medical practice, it is important that this is undertaken 
appropriately at the optimum time in the patient diagnostic pathway. In this paper, we draw 
on the experiences of those involved in an early implementation study modeling how 
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expanded access to genetic testing could be achieved in practice: The Genetic Testing in 
Epithelial Ovarian Cancer (GTEOC) Study. The quantitative arm of the GTEOC Study, 
concerned with genetic testing strategy, mutation identification rate, cost consequences 
analysis, and quantitative analyses of psychological impact and acceptability is reported 
elsewhere (Plaskocinska et al. 2016). Qualitative work is vital at this initial stage to enable 
the development of effective training for staff involved in these new clinical pathways. Few 
previous studies have explored timing of diagnostic genetic testing. Regarding the GTEOC 
study, we use the term ‘universal genetic testing’ (UGT) as this best fits the purpose and 
strategy. In the literature reviewed, there is reference to ‘rapid genetic testing’ (RGT) or 
‘treatment focused genetic testing’ (TFGT); for clarity, we will use the term RGT when 
referring to previous research. Though there are commonalities (i.e. testing relatively soon 
after diagnosis), we differentiate between these terms and UGT as the other terms do not 
capture the element of broadening access to genetic testing.
Previous qualitative research has suggested that the influence of RGT on treatment decisions 
for EOC overrides other psychosocial concerns (Gleeson et al. 2013; Meiser et al. 2012). A 
recent qualitative study involving both breast and ovarian cancer patients describes women’s 
preferences for personalized professional involvement to enable decision making (Augestad 
et al. 2017). However, this study took place when the results of genetic testing did not 
influence treatment decisions and only one of the seventeen participants had a 
BRCA1/BRCA2 mutation. Younger women diagnosed with breast cancer generally have 
positive attitudes towards RGT (Zilliacus et al. 2012), though the focus on immediate 
treatment decisions may mean considering further implications of the testing is delayed. 
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Quantitative work evaluating RGT in the context of breast cancer diagnosis (Schlich-Bakker 
et al. 2006, 2008; 2009) indicates that there is no impact on short- or long-term psychological
distress of being approached about genetic testing, though in one study 43% of eligible 
patients declined counseling and/or genetic testing (Schlich-Bakker et al. 2008) highlighting 
potentially important acceptability issues. Similarly, no adverse psychosocial effects are 
reported when RGT is undertaken compared with usual care (Weavers et al. 2014, 2016). 
Almost all women offered it choose to access rapid genetic counseling, and though most 
women undergo genetic testing eventually, only 40% opted for rapid access to the test. 
Research is needed to better understand the motivations of this test-delay group.
The present study explores the experiences of women recently diagnosed with EOC who 
have been offered genetic testing through the GTEOC study, and those of staff who have 
discussed this testing with them. We aimed to: (i) assess the impact of UGT, and (ii) integrate
patients’ and staff perspectives on how best to support patients, families, and professionals in 
developing UGT programs.
Methods
Context: The GTEOC Study
The GTEOC Study offered genetic testing to women over 18 years old diagnosed with EOC 
within the last 12 months through six sites in East Anglia (England). Two hundred and thirty 
two women were recruited between July 2013 and June 2015, irrespective of age and family 
history of cancer. In anticipation of the movement towards routine genetic testing for 
BRCA1/BRCA2 within oncology settings, eligible women were first approached by a 
research nurse/trial coordinator at their treating hospital and provided with written study 
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information. Following this, further information was provided by the study genetic counselor 
(HS, who holds a Master’s degree in Genetic Counseling) during a telephone call. While this 
would not be considered standard “comprehensive” genetic counseling, the telephone call 
enabled the women to raise concerns and ask any questions. The written information and that 
provided orally by the study genetic counselor emphasised the potential clinical impact for 
the women themselves and their families, as well as the contribution to research. However, 
the specific information provided by the local research nurses and clinical trials co-
ordinators, who were briefed about the study, was not recorded. Genetic testing results were 
mailed to GTEOC participants and those with a mutation, variant of uncertain clinical 
significance (VUS) or significant family history of cancer were invited for face-to-face 
genetic counselling with the local Clinical Genetics department. Those with a mutation or 
VUS also received a follow-up telephone call from the study genetic counselor (HS). Please 
see Plaskocinska et al. (2016) for further details about the main GTEOC Study.
Procedure for the Qualitative Sub-study
The GTEOC Study had full ethical approval (REC12/EE/0433). Women enrolled in the 
GTEOC Study and who had received their BRCA1/BRCA2 results were eligible to take part 
in the qualitative interviews. Purposive sampling was undertaken to ensure that participants 
with each outcome of genetic testing (i.e. mutation, no mutation and VUS) were recruited. 
Consistent with IPA methodology, the sample was selected on the basis that it could offer 
insights into a particular experience from the perspective of particular people (Smith et al. 
2009). Fifteen women recruited earliest to the GTEOC Study (4-12 months since recruitment)
received an additional telephone call from the study genetic counselor (HS) and were then 
provided with written information. All six staff members who had been involved in 
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approaching potential participants for the GTEOC Study were also invited to take part using 
analogous procedures. IPA studies are conducted on relatively small sample sizes as the 
principal concern is to provide a detailed account of individual experiences (Smith et al. 
2009). Smith et al. (2009) propose that attention should be given to quality, not quantity, and 
given the complexity of most human phenomena, studies benefit from a concentrated focus 
on a small number of cases. They suggest that larger datasets can in fact inhibit the detailed 
case-by-case analysis that is called for.
Participants
The twelve women interviewed were broadly representative of the larger study population, 
with a mean participant age of 66.75 years (range 49-80). Eleven women (91.7%) were white 
British and eight (66%) had offspring. Ten women (83.3%) had been educated to secondary 
level and two (16.7%) to degree level. Two women (16.7%) had a personal history of breast 
cancer and both of these women were identified as having a BRCA1/2 mutation. Altogether, 
these women represented the different outcomes of genetic testing (mutation (n=4), no 
mutation (n=5) and VUS (n=3)). Five staff members were interviewed: four of these were 
women, three of whom are research nurses with over 10 years’ experience and one is a trial 
coordinator with less than 5 years of experience. One staff participant was male, a trial 
coordinator with over 10 years of experience. None of these staff had received any formal 
training in counseling around genetic testing.
Data Collection and Analytic Approach
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Following written consent, semi-structured, in-depth interviews were conducted, each lasting 
between 25 and 90 min. Interviews explored participants’ opinions and experiences of UGT, 
including benefits, burdens, utility of the information, and family communication. Topic 
guides were used, but conversations were reflexive in order to gather rich and nuanced data 
(Rubin and Rubin 2005). In accordance with IPA’s guiding principles, semi-structured 
interviews enable a rich, first-person account of participants’ experiences (Kvale & 
Brinkmann, 2009; Smith et al., 2009).  Participants have the flexibility to speak freely and 
develop their ideas and the interviewer may probe interesting areas that arise. HS has 
previous experience in qualitative research and has undertaken semi-structured interviews 
during her post-graduate research at Master’s and Doctoral levels. Interviews were 
transcribed verbatim by HS or AD* and anonymized; participants were given pseudonyms to 
preserve their anonymity. Transcripts were analyzed using Interpretive Phenomenological 
Analysis (IPA) (Smith et al. 1999), a method with three main theoretical underpinnings. 
Phenomenology is a philosophical approach concerned with how things appear to us in our 
experience (Shinebourne 2011). It is explicitly inductive, aiming to produce an account of 
lived experience in its own terms rather than being theory driven (Smith et al, 2009). 
Secondly, IPA understands this as an intrinsically interpretive endeavor, emphasizing sense-
making. It engages a double hermeneutic approach, whereby the interviewer makes sense of 
the participants’ explorations of the meanings of their personal experiences (Giddens 1987). 
Thus, the researcher’s own conceptions and involvement in the interpretive process are 
intrinsic to this methodological approach. Thirdly, IPA is an idiographic approach. It is 
concerned with the particular, that is, how individuals make sense of their personal 
experiences within their specific contexts, ahead of making any more general claims. Thus, 
IPA is particularly suited to exploratory studies. 
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HS read and re-read each transcript several times, documenting emergent themes. In keeping 
with IPA, these were broad and descriptive themes. Theme development was iterative and 
reflexive, contrasting patient and staff interviews. Connections between themes were noted, 
themes were clustered and organized into super-ordinate concepts and then checked back 
against the primary data. SF and C M-S undertook independent audits of the data (SF for 
GTEOC participants and CM-S for staff) to independently verify and validate the themes. 
NH-W also independently analyzed two transcripts as part of analytic validation. The final 
thematic framework was reached by consensus within this authorship sub-group.
Results
The results attend to themes relating to participants’ experiences of UGT, which are grouped 
under two themes: motivations and influences around offers of genetic testing and the 
impacts of genetic testing in ovarian cancer patients. Notably, throughout all accounts a 
further theme was emergent: ovarian cancer as the profound intrusion, whilst the impact of 
genetic testing was often minimized. This finding is an important contextualization for this 
paper. 
Theme 1: Motivations and Influences around Offers of Genetic Testing
This theme highlights the contextual nature of UGT within the wider experiences of women 
and their families at the time of ovarian cancer diagnosis, especially considerations about 
genetic testing in relation to the primary concern of the cancer diagnosis itself. It is of note 
that staff expressed surprise at the variability of women’s interest in genetic testing, as they 
had presumed uptake by almost all women. 
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Genetic Testing was Just Not Disruptive in the Context of Cancer Diagnosis
Participants suggested that undergoing genetic testing was not a substantial concern for them 
in the context of having been diagnosed with ovarian cancer and indeed, being confronted 
with their own mortality. In some cases, there were explicit comparisons between the 
considerably bigger impact of cancer diagnosis and treatment with other matters, such as 
genetic testing, which paled into insignificance as demonstrated in the interview with Glenys,
when asked about when she was offered genetic testing:
Glenys: I don’t remember the ins and outs. I just know that they said that Dr (name 
removed) would like to see me. 
Interviewer: Yeah. To discuss it. 
Glenys:     That was all. Yeah.
Interviewer:      Yeah. 
Glenys:     I mean I was going- I was going through chemo at the time an, you know, I 
just wanted to get through the chemo (laughing tone) I really didn’t really care
about- you know, as long as I was gonna be all right, that was all I was 
concerned about. 
Interviewer:      Yeah, yeah. 
Glenys:     And that’s made a big difference to my attitude to all the tests and studies and 
everything.
Interviewer:      Yeah. 
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Glenys:    Because I knew that once, you know, the op had been done, that I was ok. 
And every time I had a test, a scan or whatever, I was told that I was in the 
clear. 
Interviewer:      Yeah. 
Glenys:     That made a huge difference to my attitude, you know. 
 (Glenys, 55 years old, no BRCA1/2 mutation identified, mutation identified in another 
inherited cancer gene)
Glenys foregrounds her treatment, explaining that as her primary concern ahead of anything 
else. In other interviews, the contrast is more implicit. Unlike the women’s accounts of 
cancer diagnosis and treatment, in which there are spontaneously given, long descriptions of 
specific events and the derailing impact on the women’s lives, the accounts about genetic 
testing tended to be minimal, despite interviewer prompting for further detail. Indeed, in 
several cases, participants could not recount when they were initially offered genetic testing 
and explained that such offers were not problematic. Consider the two extracts below, taken 
from the interview with Sandra, a 68-year-old woman who had a BRCA1/2 mutation 
identified. Earlier in the interview she had discussed her previous diagnosis of breast cancer 
as well as her strong family history of cancer, including both of her parents and more distant 
relatives. First is an extract in which she explores the dramatic and disruptive events of her 
diagnosis of ovarian cancer and the lead up to it. At the time, she was also the primary carer 
for her husband, who had a chronic health condition:
Sandra: By then, I’d stopped eating because I was getting my husband a meal but 
having to keep popping outside for fresh air while I was even cooking his 
meal. And I thought, “I can’t go on like this.” And I’d lost- For about a 
11
month they did that. All of June. And then by July I’d lost- I lost four stone 
in about three weeks. 
Interviewer: Yeah. Wow.
Sandra: And I had very very little energy and I was beginning to get really worried, 
not for myself but for my husband cos I couldn’t- I was getting to feel I 
couldn’t look after him. And I went to see the doctor and I hadn’t seen her 
for nearly two months and she said, “You’ve lost a lot of weight,” and I 
said, “Yeah, I’m not feeling at all well.” And I said, “I keep having- The 
doctor said last week he’d send the nurse in” I said “and she did me three 
suppositories and I had to drink five drinks straight away” I said “and I still 
didn’t go.” So she rang the hospital and they said “Come in immediately”.
Interviewer: Yeah
Sandra: I came home and sorted pills and things for my husband, got myself ready, 
went in and of course by midnight they’d done X-rays and I knew I hadn’t 
got a bowel blockage that was on the Tuesday night.  Thursday morning- By
Thursday I’d had scans and I’d had all sorts of things and tests, and you 
name it I’d had it. And that’s when Dr (name removed) came and said “We 
think you have secondary breast cancer”. Cos all here swelled up as well.  I 
couldn’t bend at all.  All here was tight and she said it was something to do 
with the lymph nodes but I can’t remember what it was. And she said, “You 
have secondary breast cancer and we’re ninety-nine and three-quarter 
percent sure that you have ovarian cancer and we think it’s Stage 4.” 
Interviewer: Wow.
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Sandra: Well I didn’t know what that meant and I said “Oh ok. What do we do 
now?” and she sent this little Macmillan nurse to talk to me but I couldn’t 
cope with her. (laughs) She was sweet but she was too sweet!
Interviewer: Right. Just not appropriate at that time for you at all.
Sandra: No (laughs). I didn’t need sweetness and condescension and I don’t mean 
that in a nasty way. She was a lovely lady and she was trying her best and 
probably for another type of character, she would’ve been right. They 
could’ve sat and held hands and the patient could’ve cried and- but it 
annoyed me, I didn’t need it. I didn’t want it.  I just wanted to process 
everything in my own mind and decide how I felt and what was going to 
happen. And about five minutes after the doctor had gone and she’d gone, I 
asked her to go erm it suddenly hit me then and I just thought I’m in a room 
full of people so I just took myself-
Interviewer: You were you on a ward were you?
Sandra: Yeah, I was on the ward, yeah. And erm I just took myself off into the loo, sat 
on the floor, had a good cry and thought, “Right, you’ve got it out of your 
system, let’s get started.”
In contrast with the physical, emotional and logistical impacts surrounding her cancer 
diagnosis, Sandra had little to say about her experience of genetic testing, which was 
described as unproblematic:
Interviewer: Do you have any kind of comments or feedback about going through that 
genetic testing?  I mean I know we spoke, so once you’d said you were 
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interested, you were put in touch with me.  Was that ok having that done by 
phone?
Sandra: Yeah, it wasn’t a problem to me. 
Interviewer: Yeah ok, that’s good
Sandra: I didn’t find it difficult or upsetting or anything.
Interviewer: Was there enough information and so on for you?
Sandra: Oh yes yes.
Interviewer: Yeah and I mean obviously, you were given a positive result-
Sandra: I think anyone with a normal intelligence could understand it easily.  
Interviewer: Good.
Sandra: Yeah I didn’t find it a problem at all.
Interviewer: Yeah and you felt you could get any questions answered that you wanted to?
Sandra: Yes, yes, yes and I felt it was a good thing to do and I think if everybody did
it when they were asked, then it all helps with knowledge and future 
information.
Women valued the minimal logistical impact incurred by having genetic testing through the 
study, though again this may be a comparison with the direct disruption of cancer. Joy, a 49 
year old, who had no BRCA1/2 mutation identified discusses the minimal disruption (and 
impact to her) of genetic testing:
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Interviewer: So, did you have any concerns and anxieties?
Joy: No, because it’s very- it’s not invasive, it’s not- did- It was just filling in 
forms. It wasn’t like I had to go and have a surgical procedure for it or 
anything like that. Or take some medicine for it or anything….I wasn’t 
relieved because it didn’t really matter to me because I still had ovarian 
cancer, you know. It wasn’t a positive or a negative for me but-  I did tell my 
sister straight away, so she could put her daughter out of her misery. 
Social Altruism and Family Considerations were Highly Persuasive
Two main social influences were discussed by participants as impacting UGT uptake 
decisions: altruism and family involvement. This covers both how the women considered 
others in their decision-making process, and also how others are reported to have actively 
influenced that choice. Every participant made reference to altruism as a motivation for them 
to have genetic testing. Primarily this was oriented towards their family, in particular their 
daughters, although other female relatives were also discussed, as demonstrated by Justine, a 
71-year-old in whom no BRCA1/2 mutation was identified:
Interviewer: So, do you remember who first mentioned that to you? 
Justine: Yes. It was now- it was either the chemo doctor or it was the surgeon, one or 
the other said that I’d be- And I said, ‘Of course’. Obviously, because I’ve got
a niece, and obviously, I needed to know for her.
Interviewer:    You have a sister- is it sister? a brother?
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Justine: I’ve got two brothers, yeah. But- And I’m quite happy to sort of take part in 
things, if it helps other people, obviously. I mean, it’s not just me, is it? I’m 
just sort of one. Yeah.
Interviewer: So, in general you’re quite happy to take part and so on.
Justine: [Yes, yes]. Oh, yes. Of course.
Interviewer: So, this wasn’t something that it was a big decision to make in your mind 
then?
Justine: No, no, no. 
In many cases this further extended to unrelated others, as exemplified by the interview with 
Joy (no BRCA1/2 mutation identified):
Interviewer: The genetic testing as well, do you think it was um an appropriate time to be 
approached about it?
Joy:     I don’t think that it would’ve mattered when you approached me to be honest, 
at the time I was probably not very with it to be perfectly blunt.
Interviewer: Yeah.
Joy:     But if it needed to be done then then it needed to be done then. It didn’t upset 
me. 
Interviewer: Yeah, Ok.
Joy:     And it didn’t cause me a problem. 
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Interviewer: And it’s probably not something that you were overly concerned about-?
Joy:     No. 
Interviewer: Thinking it was relevant to you, which in the end it didn’t turn out to be?
Joy:     No. I didn’t think it was relevant to me. But I thought if I could help- if it 
would help diagnose somebody earlier in the future, then it’s worth doing.
Here Joy backgrounds the significance of genetic testing at the time it was offered, due to her 
health status at the time. Nevertheless, she demonstrates that she had a willingness to go 
ahead with it. The interviewer then draws upon a comment Joy had made earlier in the 
interview about the limited relevance of genetic testing to herself and her family, primarily 
because she does not have children. Joy then draws upon the notion of future oriented 
altruism towards other women at risk of ovarian cancer.
All staff participants indicated altruism was the primary motivation of participants, as 
demonstrated by the following extract involving Stephen, a clinical trials coordinator:
Interviewer: It’d be good to hear your opinions on the sort of pros and cons of offering 
genetic testing to people quite soon after they’re diagnosed. 
Stephen: I guess the pros are that most patients, you know, when you speak to them are 
very keen to know why they’ve got cancer. Most people you speak to, they 
want to know why, what the impacts are for their families, children, siblings 
and so on. 
Interviewer:    Yeah.
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Stephen: I don’t see any real disadvantages.
Beyond the internal motivations of individual participants, family involvement emerged as a 
more extended component of this theme. Some women discussed their interactions with 
relatives, noting their interest or otherwise in genetic testing. This impacted upon the 
women’s decision making about UGT, as discussed by Lynn (no BRCA1/2 mutation 
identified):
Lynn: Jessica (daughter) never says much but our Laura (daughter) said, “Mum is it 
like contagious or can we get it?”
Interviewer: Yeah, yeah. 
Lynn: You know, does that mean because you’ve got it are we going to get it?
Interviewer: Yeah, yeah. 
Lynn: Jessica (daughter) tends to be quieter about things.
Interviewer: But it’s a question that comes to mind? 
Lynn: But it’s a question that comes to mind. And you know, she’s asked since. And 
that’s why we did- agreed to the genetics. We said, “Why not”, you know. We
were tested- many years ago they looked into the genetics of the girls because 
Laura (daughter) was born with half her waterworks missing. 
Sometimes family involvement complicated decision making and led to ambivalence in the 
women:
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“When I got the [invitation to GTEOC] letter, I spoke to [sister] about it, and [sister] thought,
“No, you’re doing enough already”. And then I was thinking, “Oh should I go through with it
or not?”” (Rita, VUS identified in BRCA1/2)
Though Rita had expressed that she would like to pursue genetic testing, she now felt 
conflicted in her decision making, between her own desire on the one hand and her 
responsibilities towards her sister and other relatives on the other. Furthermore, staff gave 
examples of family members, particularly offspring, swaying a woman’s decision to 
participate or not, because of the impact on themselves: 
“I  had  one  where  there  were  two  daughters.  One  daughter  was  quite  happy,  the  other
daughter wasn’t, she didn’t want to know and- I said, “Well it’s got to be something you all
discuss as a family really and decide what’s best for you at this point in time.”…And they did
and decided not  to  go into the  trial.  So you know, that’s  what  it’s  gotta  be,  hasn’t  it?”
(Research Nurse, Sally)
Here we see an account of complex negotiations. Firstly, the woman offered UGT must 
consider her own desires and anticipate those of her offspring. This can be complicated 
further by division within the family unit. Secondly, we have some insight into how Sally 
negotiates her active and dynamic role in managing this situation as she seeks to facilitate 
discussion and agreement within the family.
Staff Anxieties Regarding Additive Emotional Burden to some Already Vulnerable
Patients
Unlike the women’s accounts, staff did not minimize the psychological effects of offering 
UGT so soon after a diagnosis of ovarian cancer. Rather, they told accounts of thoughtful 
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consideration of the best time to approach women on this subject. This is intricately related to
the context of their experiences of ovarian cancer diagnosis as burdensome and 
overwhelming. This theme speaks powerfully of the group which are so difficult to access 
directly - those women who decline UGT. In some cases, fear is the reason why women 
decline UGT, as Margaret, a research nurse explains:
 
Interviewer: You mentioned that most people have been really positive about it [UGT]. 
For those that haven’t, or have- can you just sort of expand that a bit more 
about sort of what has gone on for them?
Margaret: Very few that haven’t.  One has just been, “I really don’t want to know.  It 
just scares me and it’s not something I’ll ever want to look into.”  But the 
only other couple have been if they just haven’t got any family at all, they 
don’t know their family history.  They’re either adop- we had one who’s 
adopted, one who’s had no children and just it’s very much the minority. 
Interviewer: Yeah.
Margaret: I mean every patient virtually I’ve spoken to will have wanted to certainly go 
ahead onto the conversation with yourself.
Another aspect to this theme is the pre-existing emotions the women experience due to their 
recent ovarian cancer diagnoses:
“Once they’ve had a diagnosis they’re bamboozled with the idea of all the treatment options 
in front of them or they might be post-surgical and facing chemo…and- they’re probably not 
at the most receptive point to consider this. They’re already on this sort of rollercoaster, 
they’re in shock.” (Research nurse, Fiona)
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Fiona highlights the emotional burden of the cancer diagnosis and all it entails as directly 
impacting on women’s desire and capacity to contemplate decisions about UGT. Her use of 
emotive words builds a picture of someone who is not emotionally available for further 
discussions. Furthermore, staff participants related psychosocial concerns as pertinent to their
gatekeeping role when deciding whether to approach women or not, as discussed by Chloe, a 
clinical trials coordinator:
Chloe: Certainly, other people I’ve spoken to so far have been happy to be 
approached about it and I think they in general seem to think it’s a good thing,
even if they have their own personal reasons for not wanting to do it 
themselves. 
Interviewer: Ok. Yeah. So, as in they’re happy that they were approached even if they’re 
saying no?
Chloe: I don’t know about any risks, I guess- Obviously, it’s a difficult time for 
people so you have to be careful, but if we felt it wasn’t the right time to ask 
people, we’d always do what we felt was right. 
Interviewer: Yeah. So, when you say the clinicians normally approach these patients, is it 
usually the oncologist or um nurse?
Chloe: It depends on where they’re seen first, really. I think (nurse’s name) like me 
would maybe talk to patients but in a clinic setting with the surgeons. 
Interviewer: Yeah.
Chloe: And again, I don’t think we [pause] certainly when I do it, I don’t go into too 
much detail, cos given that they’re in quite an early stage in their diagnosis 
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and there’s a lot going on, I’ll make them aware that there’s a genetics test, a 
genetic study on offer that they may want to consider
Interviewer:      Yeah. 
Chloe: And if they’re happy to get some more information, I usually leave them with 
the info sheet and obviously say, if they have any questions.
Theme 2: Impacts of Genetic Testing in Ovarian Cancer Patients
This theme considers the effects of the different genetic testing results on the participants and
how they relate to their wider families. In particular, women have to negotiate risks to 
themselves and others once they receive their results.
Negative Test Results Were a Reassuring Process for Most Participants
If no mutation was detected, generally participants described feelings of reassurance and 
relief. They discuss little further impact, other than the knock-on effect of reassurance for 
their relatives, as demonstrated by Kate (no BRCA 1/2 mutation identified):
Interviewer: So when we sent this letter, was it ok to receive the results by a letter?
Kate: Absolutely fine. Yes. No problem. No. And it was quite early on as 
well. It was the- February? Yes, 5th of February, so it was quite-
Interviewer: Did it come through a bit quicker than-
Kate: early on with my- I was sort of barely- I’d only started chemo two or 
three weeks so yes it was good to receive it.  
Interviewer: What did you think then when you did get it?
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Kate: I was quite happy with it. 
Interviewer: Yeah?
Kate: Yes. Yes. 
Interviewer: Did it make you feel reassured about-?
Kate: I think that I was reassured, yes. Definitely. Yes. It meant I could tell 
my sister and my daughter. Yeah, in fact I must tell my sons then if it’s
connected with the prostate as well.
Yes, I told her [daughter] the result. Yeah and she was, you know, happy about it. (Clare, no 
BRCA1/2 mutation identified)
The accounts are minimal in detail – once given the reassurance, there was little other 
psychological impact. Some participants explained that they interpreted a negative result 
within the context of their family history of cancer. For example, women with minimal 
family history now feel that their own diagnosis was “just one of those things” (Joy, no 
BRCA1/2 mutation identified) and that the risk to relatives is minimal. Only one patient not 
found to have a BRCA1/2 mutation, Christine, continued to believe there was an 
undiscovered underlying genetic risk. Christine was the only patient without a BRCA1/2 
mutation with a strong family history of cancer which included her mother, father and 
paternal grandfather:
Interviewer: Would it have surprised you if it [genetic test] had come back positive?
Christine: What that it was-
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Interviewer: I mean if we found a gene?
Christine: That was possibly from my mother you mean or my father?
Interviewer: Yeah.
Christine: No, I’m pretty sure it was.
Interviewer: Yeah ok so you’re still fairly sure that there’s an inherited link.
Christine: Yes, because my grandfather died I think of cancer. I got his birth certificate
in there.
Interviewer: Ok.
Christine: I think my other grandfather died of it as well and my grandmother, well
you didn’t call it cancer then, did you?  I mean she died when my Mum was
only about early twenties.
Interviewer: Oh really? Young.
Christine: Yeah.
Interviewer: Possibly of cancer again. Erm so even though we haven’t found a change in
these genes, you’re still fairly confident there’s something going on in your
family?
Christine: Yeah.
Interviewer: So it wouldn’t surprise you if later down the line we found something else?
Christine: No, no, it wouldn’t surprise me.
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Interviewer: Ok. So in a sense does the fact that we didn’t find a change in the BRCA1 or
BRCA2 genes, does that not put your mind at rest or make you think any
different?
Christine: I just don’t think about it really. 
Interviewer: No.
Christine: No, I just- I do think probably I inherited it from my mother but as she had
breast cancer. But erm and she had a hysterectomy as well. 
Trading Uncertainties: Managing a Finding of a Genetic Variant or Mutation
This subtheme relates to the complex risk management that some women must undertake 
once they have received a test result indicating a mutation or VUS. In the case of a mutation 
being detected, this provides women with an explanation for their cancer, but it brings 
challenges in dealing with more quantified risks to themselves and their family, which are 
less certain outcomes. Women with a VUS (inconclusive) result are left with even higher 
levels of uncertainty, like Rita:
Interviewer: How’s that for you, having that uncertainty?
Rita: It’s a bit off, really.
Interviewer: Yeah.
Rita: Because I was thinking, well, she- coming to see her and she can definitely
give me an answer but she can’t because they’re not quite sure of one of the
genes.  She says whatever every- all of us have different genes, you know,
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abnormal genes and things like that so she can’t give them a straight answer to
say- about these genes.  Or they have to test them to find out.
Interviewer: Yeah.  Did she say what the plan is?  Is there a plan?
Rita: No, there isn’t a plan, she just said to my doctor that within three years’ time
they might get to know more about this gene and they can phone up and find
out
Interviewer: If there’s some more knowledge
Rita: [Yes], and more knowledge about it.  But for now they’re not certain what it is
Janette discussed the uncertainty that remains for her, despite her conclusive genetic test 
result. Janette was diagnosed with breast cancer thirty-five years ago (at age 28 years), and 
has remained well until now. She still has one breast and discusses the challenges of decision 
making in the face of uncertainty:
“They spoke to me, they said, you know, “it’s an eighty-five percent chance that you will get
breast cancer again or even another type of cancer”, but the BRCA gene apparently reduces
risk as you get older, but as you get older but the age er is more you know as you get older
you have more chance of breast cancer.  So, I feel I’m really- You don’t know where those
two meet so I just feel as though again I’m back to square one, where who knows?” (Janette,
BRCA1/2 mutation identified)
Here Janette grapples with knowledge about the lifetime- and age-related breast cancer risks
of someone with a BRCA1/2 mutation and what she should choose to do about her increased
risk.
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Managing Responsibilities in the Wake of Genetic Testing
Receiving the results of UGT leads to responsibilities to others which must be managed by 
the women; in particular, negotiating family communication about the test result. Mary 
demonstrates the prominent concept of ‘transferred responsibility’; that is, the importance of 
imparting the relevant information to a family member, and then foregrounding that person’s 
autonomy in how they choose to respond to the information:
“My son’s gonna contact him (other son) and go and tell him, yeah. And then it’s his choice. 
I think, I feel that he ought to know, but whether he takes it up or not, it is down to him. He 
can’t turn round later on and say, “Well you never told me” or something like that but- Cos 
he’s got a daughter and two boys.” (Mary, BRCA1/2 mutation identified)
Participants described many instances where these responsibilities were discharged without 
concern and the information was welcomed by others. However, where there are already 
fractious relationships or where relatives expressed lack of interest in genetic testing, 
communication can be problematic. The situation can become more complicated when the 
responsibility of providing genetic information comes into conflict with other perceived 
responsibilities, such as avoiding unwanted intrusion in the lives of others:
“A lot of this family I’ve had no contact with for many years and then I kept reading this
letter and I thought you know if I got this letter from somebody … I think I might be angry
too, or you know, why would you wanna tell me this when I’m happy in my life and I just
feel it’s a big intrusion, personally.” (Janette, BRCA1/2 mutation identified)
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Discussion
These findings confirm the quantitative results of the GTEOC study (Plaskocinska et al. 
2016): where UGT for BRCA1/BRCA2 is taken up, it is considered very acceptable. This 
finding is also reported by previous studies (Augestad et al. 2017; Meiser et al. 2012; 
Schlich-Bakker et al. 2006, 2008; 2009; Weavers et al. 2014, 2016; Zilliacus et al. 2012). No 
mutations or VUS will be identified in most women, and according to our analysis women 
are likely to find this reassuring. However, some of this reassurance will be false as a small 
proportion of women will have a mutation in BRCA1/2 that has not been identified due to 
technical limitations and others will have a mutation in another ovarian cancer predisposition 
gene not tested for, or as yet undiscovered. We suggest that an important factor in the 
acceptability of UGT is the ease with which genetic testing can take place, without creating 
additional burdens.
Practice Implications
Our analysis has gone beyond most previous studies by demonstrating that individuals 
consistently position UGT within the wider context of a recent diagnosis of EOC and 
treatment, which are already burdensome. We suggest that this is generally in one of two 
ways:
1. Women (and/or their families) are willing to undergo UGT, but have limited scope for
attending to the issues at present due to their cancer diagnosis
2. Women (and/or their families) are distressed or anxious when faced with UGT and 
experience contemplating it as additionally burdensome
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The former raises interesting issues for discussion about informed consent and the timing of 
genetic testing, particularly given that in their retrospective accounts a number of women in 
this study could not remember discussions about UGT. Furthermore, it highlights the 
importance of involving knowledgeable health professionals in order to explore what many, 
from our analysis, experience as confusing uncertainty. The latter may shed some light on the
limited uptake of genetic testing soon after cancer diagnoses reported to date (Schlich-Bakker
et al. 2008). It is important that these concerns and needs are addressed, particularly as 
genetic testing is increasingly becoming part of routine medical care. This finding highlights 
the need for a continued individualized approach in clinical practice, with support and space 
for discussion available if desired (Foster et al. 2006). In the fast-paced medical world with 
increasing treatment options it can be forgotten that some individuals choose to forego 
genetic testing. Anxiety is prevalent in newly diagnosed cancer patients and needs to be 
addressed sensitively (Watts et al. 2015).
Another contribution of this study is knowledge about the broader social and familial context 
in relation to UGT decision making, which very much reflect consistent findings across the 
broader genetic counseling literature. Our participants reported both the influence of 
responsibility or altruism towards others in decision making and also the direct impact that 
other people have in influencing that very same decision. We do well to remember that 
people do not make decisions in isolation (D’Agincourt-Canning 2006; Hallowell et al. 
2003). Indeed, Hallowell et al. (2003) describe how women depict themselves as ‘selves in 
relation’; in generating and disclosing genetic information about themselves and their 
families, participants were motivated by their responsibility to further the autonomy of their 
relatives. D’Agincourt-Canning (2006) similarly reports participants’ orientation to both their
families and to unknown others in their decisions about genetic testing. This responsibility 
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framing bears little resemblance to theories of rational decision making, which solely focus 
on the individual and their autonomous decision (Faden and Beauchamp 1986).  As UGT 
programs are rolled out, staff must continue to relate to individuals within their family 
contexts.
Though in most instances communication with relatives about genetic testing results is 
described as unproblematic, some participants discussed challenges or barriers. As genetic 
testing becomes more widespread, this important outcome must not be side-lined or 
underestimated. Women may require additional support in disseminating information and this
can be experienced as burdensome (Hallowell et al. 2003). We suggest staff actively discuss 
the practical aspects of information dissemination with women undergoing UGT and provide 
written supportive materials. The identification of a key relative who can advocate on their 
behalf within the family may be helpful. 
Study Limitations
This study has limitations, many of which are common to qualitative work. Consistent with 
IPA methodological guidance (Pietkiewicz and Smith 2012) we included a relatively small 
number of participants; it is difficult to know whether their experiences and perspectives are 
representative of the broader population that we are interested in, though ascertaining this 
was not the aim of the research presented here. Given the knowledge of differences in 
psychosocial aspects of cancer between differing ethnic groups (Alcalá 2014), the cultural 
homogeneity of our sample was disappointing. Furthermore, we have not had direct access to 
individuals who declined consent to participate in the GTEOC Study. The interviews were 
undertaken between 4-12 months following receipt of genetic testing results and this 
introduces variability that could affect women’s responses. Additionally, only one interview 
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was undertaken with each woman and it is not known whether responses might be different at
other time points.
A further potential limitation of the study is that the study genetic counselor and interviewer 
were one and the same person. Though this strengthens the work in some ways, for example 
there was already rapport with the participants, it brings risks in other aspects. For example, 
although some critique of the GTEOC study was presented during interviews, it may be that 
the participants did not feel fully able to discuss all negative aspects of the GTEOC Study. 
Also, despite seeking to be led by the literature and the participants themselves, it is possible 
that, during interviews and analysis, HS was led by some of her preconceptions and prior 
knowledge from earlier in the program of work, though this would have been mitigated by 
the involvement of the rest of the research team during analysis.
Research Recommendations
Due to difficulties of access, current research into genetic testing shortly after diagnosis has 
focused on those who have given consent, rather than those who have declined. Given that a 
significant minority may decline genetic testing (Schlich-Bakker et al. 2008), research into 
the experiences of these people and how best to offer testing to them is important. As UGT 
programs are rolled out in a variety of cancer contexts and increasingly in the context of other
diseases, it is vital that the experiences of more diverse ethnic and cultural groups are 
included in research, in order to direct guideline development appropriately. Furthermore, 
research into other cancer and disease contexts where UGT is emerging and also longitudinal 
studies of experiences over time would be of benefit as genetic testing is increasingly applied 
in mainstream medicine.
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Conclusion
This study has highlighted important and pertinent issues, in particular, going beyond the 
specific situation of UGT to considering the broader context of women’s lives. Our findings 
have practical implications for developing contexts of UGT. The importance of the family in 
discussions and sensitive consideration of the timing of offers of genetic testing are 
highlighted. Furthermore, we emphasize the role of the clinical genetics team in providing 
support for staff rolling out UGT and for individuals receiving a genetic diagnosis and their 
families, and offer recommendations for future research.
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